We are live on ! Find out more

Schrodinger

SDGR

Market cap $2.24B

29.99 USD

-0.88

2.85%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

28.51

-1.48

4.93%

1 day

-2.85%

5 days

32.93%

1 month

-1.12%

3 months

98.35%

6 months

155.02%

Year to date

66.8%

1 year

41.8%

5 years

-45.05%

10 years

4.71%

About: Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.

Employees: 850

Healthcare Health Information Services

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 23.8%

Neutral 66.7%

Negative 9.5%

Zacks Investment Research

Earnings Preview: Schrodinger, Inc. (SDGR) Q3 Earnings Expected to Decline

Schrodinger (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Schrodinger, Inc. (SDGR) Q3 Earnings Expected to Decline

Schrödinger to Present at UBS Global Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the UBS Global Healthcare Conference. The live presentation will take place on Tuesday, November 10, 2026 at 9:30 a.m. E.T. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational pl.

Schrödinger to Present at UBS Global Healthcare Conference

Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on October 21, 2026, the company granted restricted stock units (RSUs) with respect to 5,716 shares of the company's common stock to five newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement.

Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Schrödinger to Announce Third Quarter 2026 Financial Results on November 4

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) will report its third quarter 2026 financial results on Wednesday, November 4, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform.

Schrödinger to Announce Third Quarter 2026 Financial Results on November 4

Schrödinger Research Published in Nature Reveals New Insights into Lithium-Ion Battery Chemistry

NEW YORK--(BUSINESS WIRE)---- $SDGR #AI--Schrödinger, Inc. (Nasdaq: SDGR) today announced the publication of new research in Nature that reveals critical insights into the atomic-scale structure of lithium-ion battery (LIB) electrolytes. In a joint study with researchers from Columbia University and the New York Structural Biology Center, the team discovered new insights that challenge long-held assumptions of the fundamental chemistry of lithium-ion batteries, including multi-lithium ion complexes that may.

Schrödinger Research Published in Nature Reveals New Insights into Lithium-Ion Battery Chemistry

Zacks Investment Research

Schrodinger (SDGR) Surges 7.6%: Is This an Indication of Further Gains?

Schrodinger (SDGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Schrodinger (SDGR) Surges 7.6%: Is This an Indication of Further Gains?

Selling the Meta rally, Schrödinger's Apple, Tesla from faith to hope | Market Hang

Meta jumped 11% on Monday on early traction for its Muse AI agent, and Interactive Brokers chief strategist Steve Sosnick says his own customers were selling into it: Meta was the most sold stock on the platform. Ross Gerber makes the bear case on social media and the bull case on Nvidia.

Selling the Meta rally, Schrödinger's Apple, Tesla from faith to hope | Market Hang

Schrödinger: Company Creation Is Now The Real Drug Business

Schrödinger, Inc. has undergone significant changes, including pipeline cuts and a strategic pivot away from solo clinical development. Despite software growth deceleration and pipeline setbacks, SDGR's financials improved with the Ajax sale and a stronger balance sheet. SDGR's net income turned positive in Q2 2026, aided by a $48.9M gain from Ajax and increased cash reserves to $418.8M.

Schrödinger: Company Creation Is Now The Real Drug Business

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on September 13, 2026, the company granted restricted stock units (RSUs) with respect to 2,243 shares of the company's common stock to three newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducem.

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Schrödinger, Inc. (SDGR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Schrödinger, Inc. (SDGR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Schrödinger, Inc. (SDGR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

See News Rankings

Price charts implemented using Lightweight Charts™